Clinical trials: Albuminuria
Type 2 Diabetes Mellitus, Hypertension
Shiga Microalbuminuria Reduction Trial-2
The purpose of this study is to compare the effects of a direct renin inhibitor (DRI), aliskiren, on the urinary albumin excretion in hypertensive patients with type 2 diabetes under strict blood pressure control with angiotensin…
- Trial name
- NCT01461499
- Testing
- Aliskiren, any angiotensin receptor blockers
- Where
- Japan
- Volunteers
- 237 people
- Sponsor
- Shiga University
Kidney Disease, Albuminuria
Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria
Patients with chronic kidney disease (CKD) and albuminuria are at increased risk of developing cardiovascular disease (CVD) which is often associated with hypertension, left ventricular hypertrophy, endothelial dysfunction and…
- Trial name
- NCT00625820
- Testing
- 6R BH4, Vitamin C
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Michigan
Hyperuricemia, Albuminuria
Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria
The purpose of this clinical research study is to evaluate signals of potential clinical benefit of the combination of Verinurad and Febuxostat in lowering concentrations of circulating uric acid and thus improving kidney or…
- Conditions
- Hyperuricemia, Albuminuria, Type 2 Diabetes
- Trial name
- NCT03118739
- Testing
- Verinurad 9 mg+Febuxostat 80 mg
- Where
- 18 sites in United States
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus With Diabetic Nephropathy
A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria
To evaluate the safety and efficacy of IW-1973 in patients with type 2 diabetes mellitus with albuminuria who are on a stable regimen of renin-angiotensin system inhibitors.
- Trial name
- NCT03217591
- Testing
- IW-1973
- Where
- 54 sites in United States
- Volunteers
- 156 people
- Sponsor
- Akebia Therapeutics
Non-diabetic Nephropathy
To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy
The study is designed to primarily assess the effect of aliskiren on albuminuria in patients with non-diabetic nephropathy when treated with ramipril and volume intervention.
- Trial name
- ARIA (NCT01302899)
- Testing
- Aliskiren, Hydrochlorothiazide (HCTZ), Ramipril
- Where
- 2 sites in Netherlands
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Disease, Type 2 Diabetes Mellitus
A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing albuminuria in patients with Chronic Kidney Disease with Type 2 Diabetes.
- Trial name
- NCT01847092
- Testing
- AZD1722
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Ardelyx
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
NADPH oxidase enzymes (NOX) have been implicated in the development of several diabetic complications including diabetic nephropathy. GKT137831 is the first in class NOX1/4 inhibitor.
- Trial name
- NCT02010242
- Testing
- GKT137831
- Where
- 48 sites in United States, Australia and 4 more
- Volunteers
- 136 people
- Sponsor
- Calliditas Therapeutics AB
Diabetic Kidney Disease
Rhubarb and Angiotensin Converting Enzyme Inhibitor
Rhubarb extract is a chinese herbal preparation that is used in china and other asian countries to treat constipation and chronic kidney disease.
- Trial name
- RACE II (NCT00672451)
- Testing
- rhubarb extract
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Wake Forest University
Sickle Cell Disease (SCD)
Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease
The goal of the study was to evaluate descriptively the effect of crizanlizumab + standard of care and standard of care alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle…
- Trial name
- STEADFAST (NCT04053764)
- Testing
- Crizanlizuamb, Standard of Care
- Where
- 24 sites in United States, Brazil and 9 more
- Volunteers
- 58 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Nephropathy, Chronic Kidney Disease
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
The study objective was to evaluate the safety of paricalcitol capsules and the efficacy of paricalcitol capsules for albuminuria reduction in patients with Chronic Kidney Disease (CKD) who have Type 2 diabetic nephropathy and…
- Trial name
- VITAL (NCT00421733)
- Testing
- Zemplar (paricalcitol ) capsules, Zemplar (paricalcitol) capsules
- Where
- 72 sites in United States, Germany and 8 more
- Volunteers
- 281 people
- Sponsor
- Abbott
Diabetic Kidney Disease
Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria
The primary objective of this study is to assess the effect of 2 dose levels of TMX-049 on urinary albumin excretion in subjects with Type 2 diabetes and albuminuria (a urinary albumin-to-creatinine ratio (UACR) 200 to 3000 mg/g…
- Trial name
- NCT03449199
- Testing
- TMX-049
- Where
- 55 sites in United States
- Volunteers
- 130 people
- Sponsor
- Teijin America, Inc.
Type 2 Diabetic Nephropathy
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
PF-03882845 is a compound proposed for treatment of type 2 diabetic nephropathy. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-03882845…
- Trial name
- NCT01488877
- Testing
- PF-03882845, Spironolactone
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Pfizer
Hypertension, Chronic Kidney Disease
Effects of Low Sodium Intake on the Anti-proteinuric Efficacy in Hypertensive Patient With Olmesartan
Purpose of this study 1. Intensive education for low salt diet will be enhance the anti-proteinuric effect of Olmesartan, a popular anti-hypertensive drug of angiotensin II receptor blocker, in Koreans compared to conventional…
- Conditions
- Hypertension, Chronic Kidney Disease, Microalbuminuria
- Trial name
- ESPECIAL (NCT01552954)
- Testing
- Intensive education of low salt diet
- Where
- 7 sites in South Korea
- Volunteers
- 269 people
- Sponsor
- Seoul National University Bundang Hospital
Diabetes Mellitus, Chronic Kidney Disease
Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease
This study will assess the effects of vitamin D3 supplementation (cholecalciferol; 2000 IU daily) on serum calcium levels, circulating vitamin D levels, and markers of kidney disease and cardiovascular risk among people with…
- Conditions
- Diabetes Mellitus, Chronic Kidney Disease, Diabetic Kidney Disease
- Trial name
- NCT00552409
- Testing
- Cholecalciferol
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Washington
Chronic Kidney Disease, Albuminuria
Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease
Vascular endothelial dysfunction increases cardiovascular (CV) risk and contributes to the progression of chronic kidney disease (CKD).
- Trial name
- VEMAKD (NCT02497300)
- Testing
- Spironolactone, Amiloride
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Alabama at Birmingham
Diabetic Nephropathy
A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
The study hypothesis under test is that administration of a CCR2/5 antagonist to subjects with type 2 diabetes and overt nephropathy will result in a reduction in urinary albumin, a surrogate for improved glomerular filtration.
- Trial name
- NCT01712061
- Testing
- PF-04634817
- Where
- 142 sites in United States, Argentina and 12 more
- Volunteers
- 226 people
- Sponsor
- Pfizer
Renal Insufficiency, Chronic
Omega 3 Fatty Acids in Patients With Chronic Renal Disease
To study the tolerance and efficacy of an omega 3 fatty acids supplement on renal and vascular function and inflammatory parameters in patients with chronic renal disease
- Trial name
- NCT03280615
- Testing
- Omega 3 fatty acids, Corn oil
- Where
- Chile
- Volunteers
- 100 people
- Sponsor
- University of Chile
Type 2 Diabetes Mellitus
Clinical Characteristics, Anti-hyperglycaemic Treatment Pattern and Target Attainment of Type 2 Diabetes Mellitus Patients in Older Population With or Without Albuminuria in China
This is a multi-centre, cross-sectional, non-interventional study assessing blood glucose target attainment, anti-hyperglycaemic treatment pattern and the clinical characteristics in older outpatients with Type 2 Diabetes…
- Trial name
- NCT03064841
- Testing
- No Treatment
- Where
- 18 sites in China
- Volunteers
- 1,537 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, Albuminuria
A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus
The purpose of this study is to assess the effect of canagliflozin compared to placebo on progression of albuminuria in participants with Type 2 Diabetes Mellitus receiving standard care but with inadequate glycemic control and…
- Trial name
- CANVAS-R (NCT01989754)
- Testing
- Canagliflozin, 100 mg, Canagliflozin, 300 mg
- Where
- 341 sites in United States, Argentina and 23 more
- Volunteers
- 5,813 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Kidney Disease, Hypertension
Five, Plus Nuts and Beans for Kidneys
This Five, Plus Nuts and Beans for Kidneys Study is a single center, randomized controlled trial with 2 parallel arms testing the hypothesis that delivery of nutritional advice to adopt a Dietary Approaches to Stop Hypertension…
- Trial name
- NCT03299816
- Testing
- Coaching DASH group (C-DASH), Self-Shopping DASH group (S-DASH)
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Johns Hopkins University